NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
NextCure (Nasdaq: NXTC) and private Avere Therapeutics announced a definitive all-stock merger to advance Avere’s once-weekly oral IL-23 therapy AVR-001. A $320M private placement includes $251M convertible notes. The combined company will trade on Nasdaq as AVRX under Avere’s name, expected to close H2 2026.
How this was made
The 30-second read
Why it matters
The merger combines Avere’s clinical program and Hansoh-backed development rights with NextCure’s public listing, supported by a concurrent $320M private placement to fund psoriasis Phase 2b through Phase 3 initiation and ulcerative colitis Phase 2b initiation.
Market read
Definitive M&A terms, ownership split, concurrent $320M financing, and a post-close Nasdaq ticker change create a tradable catalyst for NXTC and the future AVRX equity story.
What to watch
Closing is contingent on SEC registration effectiveness and stockholder approvals; dilution/convertible note exchange mechanics and CVR terms could materially affect post-close economics for NXTC holders.
Background
NextCure (public) is merging with privately held Avere to advance Avere’s oral IL-23 receptor antagonist AVR-001, including ex-China rights granted by Hansoh.
Ticker impact
NextCure announced a definitive all-stock merger with Avere, with NextCure stockholders owning about 1.21% of the combined company at closing.
Likely volatility around deal terms and CVR details, with direction dependent on perceived value of Avere’s AVR-001 and closing probability.
The article discloses definitive merger terms, ownership split, and a contingent value right, which are direct drivers of NXTC valuation and trading behavior ahead of shareholder/SEC registration milestones.
Market effects
Reinforces investor appetite for oral IL-23 programs and may increase competitive focus on once-weekly dosing convenience versus existing oral IL-23 approaches.
US public-market listing for the combined entity could broaden US investor access to ex-China IL-23 rights and development updates.
Hansoh’s ex-China licensing and China Phase 2b readout schedule highlight cross-region development coordination that can influence global IL-23 competitive dynamics.
Counterpoint
The deal may be more about public-market access and runway than near-term value creation, given Phase 2b readouts are not until 2027-2028.
Key entities
- companyNextCure, Inc.
Nasdaq-listed acquirer in an all-stock merger; NXTC holders expected to own about 1.21% of the combined company at closing, plus a two-year CVR.
- companyAvere Therapeutics, Inc.
Private biotech with oral IL-23 program AVR-001; expected to become the combined company trading as AVRX on Nasdaq.
- assetAVR-001
Oral peptide IL-23 receptor antagonist with Phase 1b psoriasis data and planned Phase 2b/Phase 3 development timelines.
- companyHansoh Pharmaceutical Group Co., Ltd.
Partner granting Avere ex-China rights for AVR-001, with upfront payments and milestone/royalty economics described in the article.
